Awareness of Medication-Related Osteonecrosis of the Jaws amongst Dental Professionals in Poland
Abstract
:1. Introduction
2. Materials and Methods
Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Appendix A
- Age
- ○
- <25
- ○
- 25–35
- ○
- 35–50
- ○
- >50
- Years of professional experience
- ○
- <1
- ○
- 1–10
- ○
- 11–20
- ○
- >20
- ○
- Student
- Dental specialization
- ○
- General Dentistry
- ○
- Oral Surgery
- ○
- Conservative Dentistry and Endodontics
- ○
- Periodontology
- ○
- Prosthodontics
- ○
- Maxillofacial Surgery
- ○
- Pedodontics
- ○
- Orthodontics
- ○
- Student
- Work sector
- ○
- Public
- ○
- Private
- ○
- Public and private
- ○
- Student
- In what diseases is bisphosphonate treatment used? (please mark all that apply)
- ○
- Osteoporosis
- ○
- Multiple myeloma
- ○
- Cancer metastases to the bone
- ○
- Anemia
- ○
- Osteogenesis imperfecta
- ○
- Paget’s disease
- ○
- Hypertension
- In what way are bisphosphonates administered?
- ○
- Intravenously
- ○
- Orally
- ○
- Intravenously and orally
- ○
- I don’t know
- Is a dental examination and oral cavity sanitation necessary before starting bisphosphonate therapy?
- ○
- Yes
- ○
- No
- ○
- It does not matter
- Are you familiar with the term MRONJ—Medication Related Osteonecrosis of the Jaw?
- ○
- Yes
- ○
- No
- Which drugs are responsible for the risk of developing MRONJ?
- ○
- Bisphosphonates
- ○
- Bisphosphonates and Denosumab
- ○
- Bisphosphonates and Angiogenesis Inhibitors
- ○
- Bisphosphonates, Denosumab and Angiogenesis Inhibitors
- ○
- I do not know
- What is the clinical picture of MRONJ in the oral cavity?
- ○
- Exposed bone necrosis
- ○
- Bone necrosis outbreak without bone exposure
- ○
- Bone necrosis outbreak with or without bone exposure
- ○
- I don’t know
- Do you know the guidelines for managing patients at risk of developing MRONJ?
- ○
- Yes
- ○
- No
- Does oral ingestion of bisphosphonates carry a greater risk of developing MRONJ than if administered intravenously?
- ○
- Yes
- ○
- No
- ○
- I don’t know
- How long after completing bisphosphonate therapy are bisphosphonates present in the organism?
- ○
- Up to 1 month
- ○
- Up to 6 months
- ○
- Up to 1 year
- ○
- Up to 10 years
- Do you know what are the risk factors for MRONJ? (please mark all that apply)
- ○
- Alcohol
- ○
- Smoking cigarettes
- ○
- Poor oral hygiene
- ○
- Periodontal disease
- ○
- Poorly fitted removable prosthetic restorations
- ○
- Hyperlipidemia
- ○
- Steroid therapy
- ○
- Length of therapy
- ○
- Method of administration (oral/intravenous)
- ○
- Hypertension
- Have you encountered MRONJ in your practice?
- ○
- Yes
- ○
- No
- Would you like to know more about MRONJ?
- ○
- Yes
- ○
- No
- ○
- I do not know
References
- Ruggiero, S.L.; Dodson, T.B.; Fantasia, J.; Goodday, R.; Aghaloo, T.; Mehrotra, B.; O’Ryan, F. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. J. Oral Maxillofac. Surg. 2014, 72, 1938–1956. [Google Scholar] [CrossRef]
- Nicolatou-Galitis, O.; Schiødt, M.; Mendes, R.A.; Ripamonti, C.; Hope, S.; Drudge-Coates, L.; Niepel, D.; Wyngaert, T.V.D. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2019, 127, 117–135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Di Fede, O.; Panzarella, V.; Mauceri, R.; Fusco, V.; Bedogni, A.; Muzio, L.L.; Board, S.O.; Campisi, G. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention. BioMed Res. Int. 2018, 2018, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Muthukrishnan, A.; Kumar, L.B.; Ramalingam, G. Medication-related osteonecrosis of the jaw: a dentist’s nightmare. BMJ Case Rep. 2016, 2016, 1–7. [Google Scholar] [CrossRef] [Green Version]
- Beth-Tasdogan, N.H.; Mayer, B.; Hussein, H.; Zolk, O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst. Rev. 2017, 10, CD012432. [Google Scholar] [CrossRef] [PubMed]
- Fehm, T.; Felsenberg, D.; Krimmel, M.; Solomayer, E.; Wallwiener, D.; Hadjii, P. Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: Recommendations for prevention and treatment. Breast 2009, 18, 213–217. [Google Scholar] [CrossRef] [PubMed]
- Yoneda, T.; Japanese Allied Committee on Osteonecrosis of the Jaw; Hagino, H.; Sugimoto, T.; Ohta, H.; Takahashi, S.; Soen, S.; Taguchi, A.; Nagata, T.; Urade, M.; et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J. Bone Miner. Metab. 2016, 35, 6–19. [Google Scholar] [CrossRef]
- Papi, P.; Rosella, D.; Giardino, R.; Cicalini, E.; Piccoli, L.; Pompa, G. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. J. Int. Soc. Prev. Community Dent. 2016, 6, 97–104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stewart, D.L. Prosthodontic treatment of a patient taking nitrogen-containing bisphosphonates to preserve the integrity of the epithelial attachment: A clinical report. J. Prosthet. Dent. 2011, 106, 350–354. [Google Scholar] [CrossRef]
- Jacobsen, C.; Zemann, W.; Obwegeser, J.A.; Grätz, K.W.; Metzler, P. The phosphorous necrosis of the jaws and what can we learn from the past: a comparison of “phossy” and “bisphossy” jaw. Oral Maxillofac. Surg. 2012, 18, 31–37. [Google Scholar] [CrossRef]
- Campisi, G.; Fedele, S.; Fusco, V.; Pizzo, G.; Di Fede, O.; Bedogni, A. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Futur. Oncol. 2014, 10, 257–275. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coleman, R.; Body, J.J.; Aapro, M.; Hadji, P.; Herrstedt, J. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann. Oncol. 2014, 25, iii124–iii137. [Google Scholar] [CrossRef] [PubMed]
- Rosella, D.; Papi, P.; Pompa, G.; Capogreco, M.; De Angelis, F.; Di Carlo, S. Dental students’ knowledge of medication-related osteonecrosis of the jaw. Eur. J. Dent. 2017, 11, 461–468. [Google Scholar] [CrossRef] [Green Version]
- Al Abdullateef, A.Y. Awareness of Medication-Related Osteonecrosis of the Jaw (MRONJ) among oncology dental patients with risk factors for MRONJ. Master’s Thesis, The Graduate School of the University at Buffalo, State University of New York, New York, NY, USA, 2016. [Google Scholar]
- Al-Maweri, S.A.; Alshammari, M.N.; Alharbi, A.R.; Bahein, A.A.; Alhajj, M.N.; Al-Shamiri, H.M.; Alahmary, A.W.; Doumani, M. Knowledge and Opinions of Saudi Dentists Regarding Dental Treatment of Patients Undergoing Bisphosphonates. Eur. J. Dent. 2020, 14, 144–151. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tanna, N.; Steel, C.; Stagnell, S. AWARENESS OF MEDICATION RELATED OSTEONECROSIS OF THE JAW AMONGST DENTISTS AND DOCTORS IN THE UK. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2017, 124, e193. [Google Scholar] [CrossRef]
- Al-Samman, A.A.; Al-Ani, R.S. Across-sectional survey on medication-related osteonecrosis of the jaws’ knowledge and awareness in a sample of dental society. J. Cranio-Maxillofac. Surg. 2019, 47, 926–931. [Google Scholar] [CrossRef]
- Patil, V.; Acharya, S.; Vineetha, R.; Nikhil, K. Awareness about medication-related osteonecrosis of the jaw among dental professionals: A multicenter study. Oral Heal. Prev. Dent. 2020, 18, 505–509. [Google Scholar] [CrossRef]
- Al-Eid, R.; Alduwayan, T.; Bin Khuthaylah, M.; Al Shemali, M. Dentists’ knowledge about medication-related osteonecrosis of the jaw and its management. Heliyon 2020, 6, e04321. [Google Scholar] [CrossRef]
- Franchi, S.; Brucoli, M.; Boffano, P.; Dosio, C.; Benech, A. Medical students’ knowledge of medication related osteonecrosis of the jaw. J. Stomatol. Oral Maxillofac. Surg. 2020, 121, 344–346. [Google Scholar] [CrossRef]
- Eguia, A.; Bagán-Debón, L.; Cardona, F. Review and update on drugs related to the development of osteonecrosis of the jaw. Medicina Oral Patol. Oral y Cir. Bucal 2020, 25, e71–e83. [Google Scholar] [CrossRef]
- E Marx, R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J. Oral Maxillofac. Surg. 2003, 61, 1115–1117. [Google Scholar] [CrossRef]
- Rahman, Z.; Nayani, S.; Anstey, H.; Murphy, M. A survey evaluating the awareness of MRONJ within the Birmingham GMP community. Oral Surg. 2018, 12, 22–29. [Google Scholar] [CrossRef]
- McGowan, K.; McGowan, T.; Ivanovski, S. Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis. 2018, 24, 527–536. [Google Scholar] [CrossRef] [PubMed]
- Dunphy, L.; Salzano, G.; Gerber, B.; Graystone, J. Medication-related osteonecrosis (MRONJ) of the mandible and maxilla. BMJ Case Rep. 2020, 13, e224455. [Google Scholar] [CrossRef]
- Göllner, M.; Holst, S.; Fenner, M.; Schmitt, J. Prosthodontic treatment of a patient with bisphosphonate-induced osteonecrosis of the jaw using a removable dental prosthesis with a heat-polymerized resilient liner: A clinical report. J. Prosthet. Dent. 2010, 103, 196–201. [Google Scholar] [CrossRef]
- Hasegawa, Y.; Kawabe, M.; Kimura, H.; Kurita, K.; Fukuta, J.; Urade, M. Influence of dentures in the initial occurrence site on the prognosis of bisphosphonate-related osteonecrosis of the jaws: A retrospective study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2012, 114, 318–324. [Google Scholar] [CrossRef] [PubMed]
- Miranda-Silva, W.; Montezuma, M.A.; Benites, B.M.; Bruno, J.S.; Fonseca, F.P.; Fregnani, E.R. Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals. Support. Care Cancer 2020, 28, 5397–5404. [Google Scholar] [CrossRef]
General Knowledge about MRONJ | Total (n = 200) | Examined Groups: | The Duration of Work experience (Years): | Dentists in Work Sector: | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
G1 (n = 23) | G2 (n = 19) | G3 (n = 60) | G4 (n = 98) | p | <1y (n = 4) | 1–10y (n = 79) | 11–20y (n = 17) | p | Public and Private (n = 50) | Private (n = 47) | p | ||
Participants (%) familiar with definition of MRONJ | 94.6% | 100% | 100% | 86.7% | 97.0% | 0.014 | 100% | 89.9% | 100% | NS | 93.8% | 90.0% | NS |
Participants (%) who encountered MRONJ in practice | 47.0% | 87.0% | 42.1% | 28.3% | 51.0% | 0.00003 | 25.0% | 43.0% | 52.9% | NS | 64.6% | 24.0% | 0.00005 |
Participants (%) who know the symptoms of MRONJ | 69.7% | 82.6% | 63.2% | 66.7% | 67.7% | NS | 100% | 69.6% | 58.8% | NS | 79.2% | 58.0% | 0.02429 |
Participants (%) who know drugs which are responsible for the risk of developing MRONJ | 33.7% | 60.9% | 31.6% | 26.7% | 30.3% | 0.02298 | 50.0% | 36.7% | 23.5% | NS | 54.2% | 16.0% | 0.00007 |
Participants (%) with | Total | Examined Groups: | ||||
---|---|---|---|---|---|---|
Knowledge about Diseases | (n = 201) | G1 (n = 23) | G2 (n = 19) | G3 (n = 60) | G4 (n = 99) | p |
Treated with BP: | ||||||
Osteoporosis | 93.6% | 100% | 89.5% | 93.3% | 93.9% | NS |
Multiple Myeloma | 66.5% | 91.3% | 63.2% | 56.7% | 67.7% | 0.02757 |
Bone metastases | 84.2% | 100% | 68.4% | 80.0% | 86.9% | 0.02489 |
Paget’s disease of bone | 57.1% | 52.2% | 63.2% | 50.0% | 62.6% | NS |
Osteogenesis imperfecta | 19.7% | 17.4% | 15.8% | 23.3% | 18.2% | NS |
Correct Answers of the Participants (%) to Questions Concerning: | Total (n = 202) | Examined Groups: | ||||
---|---|---|---|---|---|---|
G1 (n = 23) | G2 (n = 19) | G3 (n = 60) | G4 (n = 100) | p | ||
BP’s administration (oral and IV) | 93.1% | 100% | 89.5% | 88.3% | 93.9% | NS |
Dental check before BP treatment (Yes) | 96.0% | 95.7% | 94.7% | 93.3% | 96.0% | NS |
Length of BP persistence in the organism (10 years) | 51.5% | 87.0% | 42.1% | 36.7% | 52.5% | 0.00055 |
Greater risk of MRONJ due to oral administration versus intravenous (IV is higher) | 58.9% | 91.3% | 42.1% | 53.3% | 57.6% | 0.00462 |
Answers of Participants (%) to the Question about of MRONJ Risk Factors | Total (n = 202) | Examined Groups: | ||||
---|---|---|---|---|---|---|
G1 (n = 23) | G2 (n = 19) | G3 (n = 60) | G4 (n = 100) | p | ||
Poor Oral Hygiene (correct) | 93.1% | 100% | 84.2% | 95.0% | 91.9% | NS |
Periodontal Disease (correct) | 93.1% | 100% | 84.2% | 95.0% | 91.9% | NS |
Denture wearing (correct) | 82.3% | 78.3% | 79.0% | 81.7% | 83.8% | NS |
Tobacco use (correct) | 80.8% | 65.2% | 84.2% | 80.0% | 83.8% | NS |
Steroid therapy (correct) | 54.7% | 43.5% | 63.2% | 50.0% | 58.6% | NS |
Length of therapy (>3y) | 75.9% | 87.0% | 79.0% | 73.3% | 74.8% | NS |
Manner of administration (IV) | 56.7% | 82.6% | 57.9% | 53.3% | 52.5% | NS |
Hypertension (incorrect) | 84.7% | 95.7% | 79.0% | 88.3% | 81.8% | NS |
Hyperlipidemia (incorrect) | 80.3% | 91.3% | 84.2% | 78.3% | 77.8% | NS |
Alcohol (incorrect) | 47.3% | 60.9% | 57.9% | 55.0% | 37.4% | 0.04822 |
Knowledge about MRONJ | Total (n1 = 200) (n2 = 201) | Examined Groups: | ||||
---|---|---|---|---|---|---|
G1 (n = 23) | G2 (n = 19) | G3 (n = 60) | G4 (n1 = 97) (n2 = 98) | p | ||
Participants (%) who declare that they know the guidelines of MRONJ treatment | 55.2% | 87.0% | 26.3% | 41.7% | 60.8% | 0.00009 |
Participants (%) who want to know more about MRONJ | 96.0% | 95.7% | 89.5% | 96.7% | 98.0% | NS |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Teślak, M.; Sobczak, H.; Ordyniec-Kwaśnica, I.; Kochańska, B.; Drogoszewska, B. Awareness of Medication-Related Osteonecrosis of the Jaws amongst Dental Professionals in Poland. Appl. Sci. 2021, 11, 4821. https://doi.org/10.3390/app11114821
Teślak M, Sobczak H, Ordyniec-Kwaśnica I, Kochańska B, Drogoszewska B. Awareness of Medication-Related Osteonecrosis of the Jaws amongst Dental Professionals in Poland. Applied Sciences. 2021; 11(11):4821. https://doi.org/10.3390/app11114821
Chicago/Turabian StyleTeślak, Monika, Hanna Sobczak, Iwona Ordyniec-Kwaśnica, Barbara Kochańska, and Barbara Drogoszewska. 2021. "Awareness of Medication-Related Osteonecrosis of the Jaws amongst Dental Professionals in Poland" Applied Sciences 11, no. 11: 4821. https://doi.org/10.3390/app11114821
APA StyleTeślak, M., Sobczak, H., Ordyniec-Kwaśnica, I., Kochańska, B., & Drogoszewska, B. (2021). Awareness of Medication-Related Osteonecrosis of the Jaws amongst Dental Professionals in Poland. Applied Sciences, 11(11), 4821. https://doi.org/10.3390/app11114821